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ABSTRACT
Long non-coding RNAs (lncRNAs) have been recently shown to play an important 
role in gene regulation and normal cellular functions, and disease processes. However, 
despite the overwhelming number of lncRNAs identified to date, little is known about 
their role in cancer for vast majority of them. The present study aims to determine 
whether lncRNAs can serve as prognostic markers in human breast cancer. We 
interrogated the breast invasive carcinoma dataset of the Cancer Genome Atlas (TCGA) 
at the cBioPortal consisting of ~ 1,000 cases. Among 2,730 lncRNAs analyzed, 577 
lncRNAs had alterations ranging from 1% to 32% frequency, which include mutations, 
alterations of copy number and RNA expression. We found that deregulation of 11 
lncRNAs, primarily due to copy number alteration, is associated with poor overall 
survival. At RNA expression level, upregulation of 4 lncRNAs (LINC00657, LINC00346, 
LINC00654 and HCG11) was associated with poor overall survival. A third signature 
consists of 9 lncRNAs (LINC00705, LINC00310, LINC00704, LINC00574, FAM74A3, 
UMODL1-AS1, ARRDC1-AS1, HAR1A, and LINC00323) and their upregulation can 
predict recurrence. Finally, we selected LINC00657 to determine their role in breast 
cancer, and found that LINC00657 knockout significantly suppresses tumor cell 
growth and proliferation, suggesting that it plays an oncogenic role. Together, these 
results highlight the clinical significance of lncRNAs, and thus, these lncRNAs may 
serve as prognostic markers for breast cancer.
INTRODUCTION
The human genome is actively transcribed. Of 
interest, protein-coding genes only account for ~2% 
whereas the rest of transcripts are non-coding RNAs 
including microRNAs and long non-coding RNAs 
(lncRNAs) [1]. MicroRNAs have been shown to play 
an important role in cancer initiation, progression and 
metastasis, and they may serve as potential biomarkers for 
cancer diagnosis and prognosis [2, 3]. Compared to well-
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studied microRNAs, lncRNAs are poorly characterized. 
To date, an overwhelming number of lncRNAs have been 
identified [4, 5]. Based on genomic organization and 
relationship to protein-coding genes, lncRNAs can be 
classified into five groups [6]: 1) sense; 2); antisense; 3) 
bidirectional; 4) intronic and 5) intergenic. Since lncRNA 
research is still at an early stage, the function for the vast 
majority of lncRNAs remains to be determined yet. In 
particular, little is known whether lncRNAs can serve as 
biomarkers for cancer diagnosis and prognosis.
Breast cancer is the second most common cancer in 
women in the U.S. based on the latest information from 
American Cancer Society (www.cancer.org). In 2015 
about 231,840 new cases of invasive breast cancer will 
be diagnosed in women and about 40,290 women will 
die from breast cancer. Breast cancer is a heterogeneous 
disease with a large number of genetic alterations. For 
example, six subtypes have been identified based on gene 
expression profile and the phenotype. They are luminal A, 
luminal B, tumor enriched with human epidermal growth 
factor receptor 2 (HER-2), basal-like, normal-like and 
claudin-low subtype [7–10]. For example, luminal A is the 
most common subtype characterized by the expression of 
estrogen receptor (ER), progesterone receptor (PR), Bcl-
2 and absence of HER-2. It accounts for 50-60% of the 
total breast cancer cases [8, 9]. The luminal B subtype is 
characterized by the expression of ER, PR and absence of 
HER-2. They can be differentiated from luminal A subtype 
on the basis of high Ki-67 staining which indicates higher 
proliferation rate [11]. The treatment for different subtypes 
of breast cancer is often different. However, the molecular 
pathogenesis of breast cancer remains poorly defined 
due to its heterogeneity. Although expression of group of 
specific microRNAs can be associated with cancer subtype 
[12], it is not clear about the role of lncRNAs in this aspect, 
and their clinical implication remains to be determined yet.
In the present study, we interrogated the breast 
invasive carcinoma dataset of the Cancer Genome Atlas 
(TCGA) at cBioPortal, and identified three lncRNA 
signatures that can predict overall survival (OS) or 
recurrence. Furthermore, we characterized one lncRNA 
from the signatures, LINC00657, by knockout and cell 
culture models and demonstrated that LINC00657 plays 
an oncogenic role in breast cancer.
RESULTS
Genetic alterations of lncRNAs and patient 
overall survival (OS)
Long non-coding RNAs (lncRNAs) are a very large 
mixed group of non-coding RNAs that are arbitrarily 
defined as larger than 200 bp in length [13]. Hence, we 
performed a primary search starting with 2730 lncRNAs 
primarily consisting of long intervening non-coding 
RNAs (lincRNAs) and anti-sense lncRNAs (Table S1). 
The cBioPortal recognized 2,553 of them as valid names 
(Table S2). Although the vast majority of them had no 
alterations, there were still quite a few lncRNAs with 
various genetic alterations. For example, 577 lncRNAs 
had alterations with alteration frequency ranging from 1% 
to 32% (Table S2). Forty five lncRNAs had alterations 
in 10% cases or above (Table S2); 10 of them (PVT1, 
CCAT1, LINC00536, PCAT1, PCAT2, LINC00861, 
CCDC26, LINC00977, BAALC-AS2 and LINC00535) 
accounted for a total of 40% cases (Figure 1A). These 
lncRNAs were all on chromosome 8q (Figure S1A) 
and heavily overlapped, primarily due to copy number 
alteration (CNA). Among them, PVT1 had the highest 
frequency (32%) and the lowest was LINC00535 with 
16% frequency. Of note, not all amplifications led to 
upregulation; instead only 2 of them, PVT1 and BAALC-
AS2, had upregulation (Figure S1B). No downregulation 
or mutations (missense or truncating mutation), were 
found. Importantly, each of these lncRNAs except 
for PVT1 revealed significant associations with OS 
(Table S2). When all 10 lncRNAs were combined, their 
alterations were also significantly associated with OS 
(Logrank test p = 0.0365) (Figure 1B).
Since this primary search included all three 
parameters (mutation, CNA and RNA expression) and most 
of alterations were due to amplification and upregulation 
(Figure S1B), we determined whether a single feature is 
able to predict patient outcomes. This search identified 
27% frequency for CNA alone and they were associated 
with OS and logrank test p value was 0.00845 (Figure 1C) 
among 960 samples. However, when expression was used 
as a sole criterion, none of these 10 lncRNAs was able to 
predict outcomes with a significant p value (not shown). Of 
interest, all of them were located on chromosome 8q (from 
8q22 to 8q24) (Table S3).
In this regard, chromosome 8q24 has been 
identified in a large scale study as the most frequently 
amplified region linked to different cancers [14, 15]. The 
well-known oncogene Myc is at chromosome 8q24.21. 
To determine whether these lncRNAs are closely 
associated with Myc, we chose 2~3 genes from each 
chromosome band from 8q21.13 to 8q24.3 to search the 
alternations of putative copy number. The farer from 
Myc, the smaller the changes of copy number become 
(Figure S2A & B), suggesting that 8q24.21 is the center 
of CNA. Although 8q24 is believed to be a susceptible 
region, our analysis suggested that CNA for these 
lncRNAs may involve an entire region from 8q11.1 to 
8q24.3, and it is associated with OS.
Alterations of lncRNAs in RNA expression 
and OS
CNA accounts for the large part of genetic 
alterations, and these data are obtained largely through 
genomic DNA copy number arrays [16]. Given that deep 
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sequencing becomes widely used and it provides more 
valuable information, we tried to determine whether 
deregulation of lncRNA expression (RNA-seq) alone can 
predict patient survival outcomes. A secondary search for 
significant predictors was performed in 1098 samples. 
Compared to CNA, alterations of gene expression 
were less frequent. For example, only 8 lncRNAs 
were above 10% alteration frequency and 95 lncRNAs 
revealed alternations in above 5% alternation frequency 
(Table S2). Using Onco Query Language (OQL) EXP>2, 
we found that 275 of 1098 cases had upregulation for 
LINC00657, LINC00346, LINC00654 and HCG11; 
total alteration frequency for these 4 lncRNAs was 26% 
(Figure 2A). Unlike the first lncRNA signature primarily 
due to CNA that all lncRNAs were clustered (Figure 1A), 
these 4 lncRNAs were well separated (Figure 2B). For 
example, they were either on different chromosomes or 
they were at least 29 Mb apart if they are on the same 
chromosome. Together, the association between lncRNA 
upregulation and OS was highly significant (p = 1.432e-
5) (Figure 2C). In contrast to the first signature, CNA 
of these 4 lncRNAs had no association with OS (Figure 
S3). Individually, LINC00657 revealed 11% frequency of 
alterations in 1098 samples and was the highest among 
these four lncRNAs. Its upregulation was significantly 
associated with OS (Figure S4A). The upregulation 
frequency and p values for the other 3 lncRNAs 
association with OS were shown in Figure S4B~D. Of 
note, upregulation of these lncRNAs had no association 
with recurrence (not shown).
A lncRNA signature for recurrence
Recurrence is a major concern for cancer survivors. 
Since the first two signatures were not able to predict 
recurrence, next we searched for a lncRNA signature 
Figure 1: Identification of the first lncRNA signature associated with overall survival. A. Top 10 lncRNAs based on alteration 
frequency primarily due to CNA and upregulation. B. Kaplan–Meier curve for OS due based on alterations of these 10 lncRNAs (CNA and 
upregulation). C. Kaplan–Meier curve based on alterations of these 10 lncRNAs (CNA alone).
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for recurrence. There were 68 cases of recurrence in 
this cohort (Table S4). We found that upregulation of 
18 lncRNAs with p value <0.05 was associated with 
recurrence (Table S5). To determine the optimal number 
of lncRNAs for prediction of recurrence, we adopted 
a stepwise forward selection approach based on Cox 
model to identify lncRNAs significantly associated with 
recurrence. 1) All variables were individually included in 
the Cox model on recurrence. The variable with smallest 
p value and below the 5% threshold was first selected. 2) 
First, the remaining variables were evaluated in the Cox 
model on recurrence with previously selected variable(s). 
Next, the variable with smallest p value and below 5% 
threshold entered the model. Finally, if any variable 
became insignificant after inclusion of the new variable, 
the insignificant variable was removed. We repeated 
step 2 until none of the remaining variables having p 
value less than 0.05. 3) All possible models based on the 
selected variables are evaluated by AIC. The model with 
the smallest AIC value was determined as the optimal 
model.
Based on AIC estimation, 9 of 18 lncRNAs were 
selected as a signature for prediction of recurrence (Figure 
3A & 3B). Individually, they were upregulated with 
alteration frequency of 2~5%, and together about 28% in 
a total of 1105 samples (Figure 3A). Thus, this Cox based 
Figure 2: LncRNA signature for OS based on RNA expression. A. Upregulation of LINC00657, LINC00346, LINC00654 and 
HCG11 with alteration frequency. B. Organizations of these 4 lncRNAs and chromosome locations. C. Upregulation of these 4 lncRNAs is 
significantly associated with OS as shown by Kaplan–Meier curve.
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search generated a third lncRNA signature consisting 
of LINC00705, LINC00310, LINC00704, LINC00574, 
FAM74A3, UMODL1-AS1, ARRDC1-AS1, HAR1A and 
LINC00323 (Figure 3B). Upregulation of this signature 
(exp > 2.0) was found in 228 of total 943 follow up cases; 
it was distinctly different from the no upregulation group 
(exp ≤ 2.0) with Gray’s test p < 0.001 (Figure 3C).
Association of lncRNA signatures with 
clinicopathologic features
Based on RNA expression we identified 2 signatures 
(signature 2 and 3) consisting of 13 lncRNAs capable of 
predicting OS or recurrence. Thus, we determined any 
association of these lncRNAs with clinicopathologic 
features including age, tumor stage, metastatic status, 
ethnicity as well as the stature of ER, PR and HER-2. 
Among them, we found no significant association with 
age, tumor stage, metastatic status or ethnicity. However, 
their expression was associated with HER-2. For 
example, although expression of signature 2 (LINC00657, 
LINC00346, LINC00654 and HCG11) was associated 
with overall survival in both HER-2 positive and HER-2 
negative cases, the logrank test P-value was much smaller 
for HER-positive than for HER-2 negative cases (Figure 
4A & 4B). Furthermore, in HER-2 positive patients 5 year 
survival rate was about 90% for cases with upregulation 
of this signature compared to ~65%. In contrast, in HER-2 
negative patients 5 year survival rate was ~85% for cases 
with upregulation of this signature compared to ~65% for 
cases without upregulation, implying poorer prognosis 
for HER-2 positive patients with upregulation of this 
signature than for HER-2 negative patients. For signature 
3 we found that 5 year survival rate was about 90% for 
cases with upregulation of this signature compared to 
~80% for cases without upregulation (Figure 4C). In 
contrast, in HER-2 negative patients 5 year survival rate 
was ~90% for cases with upregulation of this signature 
compared to ~65% for cases without upregulation (Figure 
4D), suggesting poorer prognosis for HER-2 negative 
patients with upregulation of this signature.
Next, we examined associations of alterations 
for individual lncRNAs derived from signature 2 and 
3 with ER, HER-2 or triple negative. Based on initial 
Figure 3: LncRNA signature for recurrence based on RNA expression. A. Upregulation of 9 lncRNAs with alteration frequency. 
B. Nine lncRNAs are selected as a signature for prediction of recurrence based on AIC estimation. C. Upregulation of these 9 lncRNAs is 
significantly associated with recurrence.
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p values, 11 of 13 lncRNAs were associated with ER 
status (Table S6). For example, in ER positive patients, 
LINC00657 regulation accounted for 60%, but no 
upregulation accounted for 71% In HER-2 positive 
patients, 34% had upregulation of LINC00654 upregulation 
accounted for 34%, no upregulation accounted for 66%. In 
the triple negative group, alteration for each of 6 lncRNAs 
(HCG11, LINC00310, LINC00704, UMODL1-AS1, 
ARRDC1-AS1 and HAR1A) was significantly higher than 
no alteration (Table S6).
Since the alteration frequency for each of these 
lncRNA varies, along with 3 clinical conditions, to 
integrate these variations, we applied the Bonferroni 
correction to control the overall type I error rate at 5%. The 
Bonferroni-adjusted P-value was calculated by multiplying 
the raw P-value by 39. Table 1 shows the adjusted P-values 
for associations between alterations of lncRNAs and 
ER, HER-2 and triple negative status. After adjustment, 
none of the lncRNAs was significantly associated with 
HER-2 status. HCG11 and UMODL1-AS1 were both 
significantly associated with ER and triple negative status. 
Status of ER was also significantly associated with a few 
other lncRNAs, including LINC00346, LINC00654, 
LINC00704, and ARRDC1-AS1.
LINC00657 is a potential oncogenic gene
Upregulation of these lncRNAs is associated with 
overall survival or recurrence, suggesting that they may 
play an oncogenic role. Hence, we selected LINC00657 
Figure 4: HER-2 status and OS or recurrence. A & B. A poorer OS with upregulation of signature 2 in HER-2 positive patients 
than in HER-2 negative patients. C & D. A higher recurrence with upregulation of signature 3 in HER-2 negative patients than in HER-2 
positive patients.
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Table 1: Alterations of lncRNAs associated with ER, PR and HER-2
 ER HER-2 Triple negative













LINC00657 Alteration (N=114) 68 (60%) 0.479 21 (18%) 1.000 20 (18%) 1.000
 No alteration (N=845) 603 (71%)  164 (19%)  163 (27%)  
LINC00346 Alteration (N=72) 14 (19%) <0.0001 10 (14%) 1.000 16 (22%) 1.000
 No alteration (N=887) 657 (74%)  175 (20%)  167 (19%)  
LINC00654 Alteration (N=67) 23 (34%) <0.0001 23 (34%) 0.129 13 (19%) 1.000
 No alteration (N=892) 648 (73%)  165 (18%)  170 (19%)  
HCG11 Alteration (N=55) 14 (25%) <0.0001 7 (13%) 1.000 33 (60%) <0.0001
 No alteration (N=904) 657 (73%)  178 (20%)  150 (16%)  
LINC00705 Alteration (N=29) 14 (48%) 0.514 4 (14%) 1.000 9 (31%) 1.000
 No alteration (N=930) 657 (70%)  181 (19%)  174 (19%)  
LINC00310 Alteration (N=36) 18 (50%) 0.565 5 (14%) 1.000 15 (41%) 0.063
 No alteration (N=923) 653 (71%)  180 (20%)  168 (19%)  
LINC00704 alteration (N=19) 2 (11%) <0.0001 7 (37%) 1.000 8 (42%) 0.653
 No alteration (N=940) 669 (71%)  178 (19%)  175 (19%)  
LINC00574 Alteration (N=36) 31 (86%) 1.000 4 (11%) 1.000 3 (8%) 1.000
 No alteration (N=923) 640 (69%)  181 (20%)  180 (20%)  
FAM74A3 Alteration (N=36) 25 (69%) 1.000 4 (11%) 1.000 6 (17%) 1.000




(N=42) 17 (40%) 0.002 3 (11%) 1.000 18 (43%) 0.014
 No alteration (N=917) 654 (71%)  182 (20%)  165 (18%)  
(Continued )
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to determine its effect on breast cancer because alteration 
of LINC00657 with RNA expression occurred at 11% 
frequency, the highest among the 4 lncRNA signature 
(Figure 2A). Moreover, LINC00657 has been recently 
shown to play a role in genomic stability [17]. To this end, 
we first profiled breast cancer cDNA arrays from OriGene 
consisting of 43 tumor and 5 normal. In 9 of 43 samples 
(21%) LINC00657 expression level was above a 2-fold 
of the mean expression level (Figure 5A). Consistent 
with this finding, we found that LINC00657 was also 
upregulated in breast cancer cell lines MCF-7 and MDA-
MB-231 cells as compared to non-malignant HMLE cells 
(Figure 5B).
Therefore, we knocked out LINC00657 by CRISPR/
Cas9 system (Figure S5) in LM-4142, a derivative cell line 
from MDA-MB-231 [18]. We selected two of them for 
further characterization (Figure 5C, RT-PCR data). MTT 
assays indicated that LINC00657 KO caused significant 
reduction of cell growth (Figure 5D). Consistent with 
this result, clonogenic assays indicated that the number 
of colonies was much smaller in KO cells than in vector 
control (Figure 5E). These results suggest that LINC0657 
impacts tumor cell proliferation and cell growth and thus, 
LINC00657 is a potential oncogene gene.
DISCUSSION
Despite large numbers of human lncRNAs identified 
so far, little is known whether they can serve as markers 
for cancer diagnosis/prognosis. The present study focus 
on a special group of lncRNAs from HGNC to interrogate 
the breast invasive carcinoma dataset (provisional) at the 
cBioPortal. This dataset consists of 960 complete tumor 
samples and over 1000 samples with RNA expression 
(RNA-seq) data. From over 2700 lncRNAs we identify 
three specific lncRNA signatures: 1) lncRNA signature 
based on alterations of CNA and RNA expression that 
is associated with OS; 2) lncRNA signature based on 
alterations of RNA expression alone that is associated 
with OS; and 3) lncRNAs based on alternations of RNA 
expression alone that is associated with recurrence. 
Together, our study suggests that lncRNAs are potential 
prognostic markers for breast cancer and thus further 
investigations of these lncRNAs are warranted.
Early work of biomarker discovery in breast cancer 
focuses on protein-coding genes such as Ki-67, ER, PR, 
and HER-2 [19]. For example, expression of ERα is a 
well-established prognostic factor in breast cancer patients 
[20]. Other molecular biomarkers include p53, p14ARF, 
cyclin D1, cyclin E, TBX2/3, and VEGF [21] and genetic 
mutations such as BRCA1 and BRCA2 [22]. Furthermore, 
several multigene signature have been developed in recent 
years to predict risk of breast cancer recurrence after a 
primary diagnosis [23, 24]. In particular, Oncotype-Dx, 
(Genomic Health) consisting of 21 genes, can provide 
treatment recommendations in conjunction with risk 
of recurrence [25]. Compared to protein-coding genes, 
the number of lncRNAs is much larger [26], and thus, 
lncRNAs should be a rich source for biomarker discovery. 
Therefore, potential lncRNA signatures would at least 
complement the existing biomarkers, providing additional 
information that may help improve the predictability.
Interrogation of this dataset provides a new 
perspective on the role of lncRNAs as biomarkers for 
breast cancer diagnosis prognosis. Although early studies 
have shown that lncRNAs may serve as prognostic 
markers, their functional role in prognosis may vary 
even with the same lncRNA. HOTAIR is one of the early 
identified lncRNAs and plays a significant role in gene 
regulation through remodeling chromatin structures [27]. 
 ER HER-2 Triple negative
















(N=31) 12 (39%) <0.0001 4 (13%) 1.000 13 (42%) 1.000
 No alteration (N=928) 659 (71%)  184 (20%)  170 (18%)  
LINC00323 Alteration (N=37) 24 (65%) 1.000 4 (11%) 1.000 10 (27%) 1.000
 No alteration (N=922) 647 (70%)  181 (20%)  173 (19%)  
HAR1A Alteration (N=26) 24 (92%) 0.346 3 (12%) 1.000 1 (3%) 1.000
 No alteration (N=933) 647 (69%)  182 (19%)  182 (19%)  
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Importantly, elevated expression of HOTAIR was reported 
in both primary and metastatic breast cancer and it is a 
significant predictor of subsequent metastasis and death 
[28]. Moreover, Sorensen et al showed that HOTAIR is 
a prognostic marker of metastasis in ER positive breast 
cancer from 164 patients by microarray analysis [29]. 
However, Gokmen-Polar et al [30] reported that HOTAIR 
was only a poor prognostic indicator in ER negative breast 
cancer from 952 patients in TCGA database. In contrast, 
high HOTAIR expression had lower risks of relapse and 
mortality than those with low HOTAIR expression through 
336 breast cancer patients [31]. Several possibilities 
may contribute to the conflicting results. First, detection 
methods are different in these studies, including qRT-PCR, 
microarray analysis and HOX tiling array. Second, the cut-
off value of high and low HOTAIR expression as well as 
ER status in these studies may be different. Third, there 
is a significant heterogeneity in these studies, such as 
the races, the tumor sizes and the clinical stages. These 
factors may also explain why HOTAIR does not meet the 
cut as a prognostic marker in our study. Alternatively, the 
signatures identified in this study may be more potentially 
as diagnostic markers than HOTAIR.
Although the role of these lncRNAs within three 
signatures in breast cancer remains to be determined yet, 
their association with cancer death or recurrence may 
Figure 5: Upregulation of LINC00657 in breast cancer and its promotion of cell growth and proliferation. A. Expression 
of LINC00657 in the OriGene breast cancer tissue cDNA array, as determined by qPCR. B. LINC00657 is upregulated in breast cancer cells 
(MCF-7 and MDA-MB-231) as compared to non-malignant breast cells (HMLE). C. Expression of LINC00657 in KO cells as compared to 
vector control. D & E. LINC00657 KO suppresses cell growth, as detected by MTT assays and colony formation, as detected by clonogenic 
assays. Values in B, C, D, E and F are SEM (n = 3). *, p < 0.05; **, p < 0.01.
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suggest that they play an oncogenic role. Since the first 
signature consists of lncRNAs primarily due to CNA, 
they are clustered in close association with Myc. Thus, 
the possible oncogenic role, if any, is likely from Myc. In 
particular, not all amplification cases cause upregulation 
of their corresponding lncRNAs. On the other hand, both 
the second and third signatures consist of lncRNAs solely 
due to upregulation and they are well separated, and the 
upregulation of these lncRNAs may suggest that they may 
function as drivers. In support of this notion, we showed 
that LINC00657 may play an oncogenic role. For example, 
LINC00657 KO suppresses cell growth and proliferation. 
Thus, LINC00657 may serve as not only a biomarker, but 
also a potential therapeutic target.
Given the clinical potential of these lncRNAs 
identified in this this study, it would be interesting to 
determine whether they can also be detected in the 
circulation system. In support of this possibility, recent 
studies suggest that serum lncRNAs may serve as potential 
biomarkers for hepatocellular carcinoma and breast cancer 
[32–34]. In addition, lncRNAs can also be present in 
urine. For example, prostate cancer antigen 3 (PCA3 or 
DD3) is a lncRNA that is highly overexpressed in prostate 
cancer. In particular, presence of PCA3 in urine can 
predict prostate biopsy outcome [35]. Therefore, further 
characterization of them is warranted.
Finally, in addition to biomarker discovery, this 
study provides an example of how researchers with little 
knowledge in bioinformatics can utilize the existing public 
data for lncRNA research. Given the overwhelming number 
of lncRNAs, a challenge for average research laboratories 
is how to focus on lncRNAs with clinical relevance. The 
cBioPortal might be a good start point before launching 
real experiments. The portal currently contains data from 
105 cancer genomics studies and a variety of cancer types. 
Since the dataset we used in this study is still provisional, the 
number of samples keep increasing. We expect that this may 
further enhance the predictability in future.
MATERIALS AND METHODS
Database search
The cBioPortal (http://www.cbioportal.org) is 
an open-access resource for interactive exploration of 
multidimensional cancer genomics data sets, currently 
providing access to data from more than 5,000 tumor 
samples from 105 cancer studies in the TCGA pipeline [36, 
37]. Although there are overwhelming numbers of human 
lncRNAs reported from databases, the nomenclature of 
lncRNAs is still incomplete. In this study we focused 
on those lncRNAs by HUGO gene nomenclature 
committee (HGNC) (http://www.genenames.org/) where 
we downloaded a total of 2730 lncRNAs (http://www 
.genenames.org/cgi-bin/statistics) (Table S1) for our 
analysis when this study was initiated.
Genomic data types integrated by cBioPortal included 
somatic mutations, DNA copy number alterations (CNAs), 
mRNA and microRNA expression, DNA methylation, 
protein abundance, and phosphoprotein abundance. 
The portal contained several sets of samples for breast 
cancer. From Breast Invasive Carcinoma dataset (TCGA, 
provisional) as shown in Figure S6, we chose 1) “All 
complete tumors with 960 samples (when the primary 
search was performed) or 2) tumors with mRNA data (RNA-
seq V2) from 1098 or 1105 samples. The primary search 
parameters included mutations, CNA from GISTIC and 
mRNA expression (RNA seq data) with the default setting. 
For the secondary search, we focused on RNA seq data.
Statistical analysis
All available lncRNAs were sorted by alteration 
frequency at the cBioPortal. Those lncRNAs with 
significant log-rank p values were entered the candidate 
pool to be considered for further selection. The forward 
selection was performed among the pool of candidates 
by using the Cox model on progression. The Akaike 
information criterion (AIC) was further evaluated for 
the models that were finalized at each step of forward 
selection. The model with smallest AIC value was chosen 
as the final model and the lncRNAs in the final model 
were identified as predictors of progression. The study 
cohort of breast cancer patients were divided into those 
with high expression on any of the predictors and those 
with normal expressions on these predictors. Progression 
and death without progression were treated as competing 
risks. The cumulative incidence of progression was 
estimated in the aforementioned two patient subgroups. 
The difference in cumulative incidence of progression 
between two subgroups was evaluated by the Gray’s test 
[38]. P values less than 5% were determined as significant. 
The statistical analyses were performed using the SAS 
software (version 9.3, the SAS institute) and R package 
“cmprsk” for competing risks analysis.
Cell culture
LM-4142 cells originally derived from MDA-
MB-231 were kindly provided by Dr. Joan Massagué 
(Memorial Sloan-Kettering Cancer Center) as described 
previously [18]. Cells were cultured in RPMI-1640 
medium with 10% FBS and 2mM glutamine. All culture 
media were supplemented with 100 units/mL penicillin 
and 100 μg/mL streptomycin.
qRT-PCR
Total RNA was isolated using Direct-zol™ RNA 
MiniPrep Kit (Zymo Research, Irvine, CA) as suggested 
by manufacturer. Reverse transcription was carried out by 
using RevertAid Reverse Transcriptase (Fisher Scientific) 
and random primer mix (New England BioLabs, Ipswich, 
Oncotarget20594www.impactjournals.com/oncotarget
MA). The expression of lncRNAs was detected by 
quantitative RT-PCR (qRT-PCR) using SYBR Green 
method. Analysis of qRT-PCR was performed as described 
previously [39].
Construction of plasmids
The high fidelity Phusion enzyme from Fisher 
Scientific (Pittsburgh, PA, USA) was used to amplify 
DNA fragments by PCR for cloning purpose. Dual 
gRNA targeting the entire exon of LINC00657 and 
the corresponding donor were constructed using the 
same method as described previously [40]. Dual 
gRNA was designed using WU-CRISPR [41] and their 
sequences were listed in Table S1. To increase the 
frequency of selection of complete knockout clones, we 
constructed a donor vector carrying left and right arm 
homologous to the flanking regions of the targeting sites. 
PCR was performed using human genomic DNA as a 
template and primer sets LINC00657-left-Spe I-5.1 and 
LINC00657-left-Spe I-3.1 (left arm), and LINC00657-
right-Sal I-5.1 and LINC00657-right-Sal I-5.1 (right 
arm). These two fragments were sequentially cloned 
into donor vector at Spe I and Sal I sites as described 
previously [40]. All amplified fragments were verified 
by DNA sequencing.
Knockout of LINC00657
LINC00657 has a single exon with 5,378 bps in 
length. We used a dual gRNA approach [40] to knock out 
LINC00657 by CRISPR/Cas9 system [42]. A donor vector 
carrying ~700 bp left or right arm derived from the outside 
regions of LINC00657 was used to facilitate selection of 
knockout (KO) clones. The dual gRNA construct carrying 
Cas9 and donor vector were introduced into LM-4142 
cells, respectively, by transient transfection. As a control, 
everything was same except that the dual gRNA is an 
empty vector. One week later, the transfected cells were 
subject to puromycin selection; and surviving cells were 
sorted by FACS based on GFP signal into 96-well plates 
and then expanded. Initial identification of knockout 
clones was carried out by genomic PCR, followed by qRT-
PCR, as described previously [40].
MTT assays
MTT assay was performed to determine the effect of 
LINC00657 on cell growth in 96-welll plates as described 
previously [43].
Clonogenic assays
To determine the clonogenic survival of LINC00657 
KO cells, cells from either vector control or LINC00657 
KO were seeded on 6-well plates at 1,000 cells/well. At 10 
days after seeding, colonies were fixed and stained with 
0.1% crystal violet.
ACKNOWLEDGMENTS
This work was supported by NIH grant R01 
CA154989 (YM) and NSF EPSCoR Seed Grant (ZW 
and YM).
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: 
past, present, and future. Genetics. 2013; 193:651-669.
2. Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular 
microRNA: a new source of biomarkers. Mutation research. 
2011; 717:85-90.
3. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, 
Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz 
M, Hollander NH, Andersen KK, Johansen JS. MicroRNA 
biomarkers in whole blood for detection of pancreatic 
cancer. Jama. 2014; 311:392-404.
4. Xie C, Yuan J, Li H, Li M, Zhao G, Bu D, Zhu W, Wu W, 
Chen R, Zhao Y. NONCODEv4: exploring the world of 
long non-coding RNA genes. Nucleic acids research. 2014; 
42:D98-103.
5. Volders PJ, Verheggen K, Menschaert G, Vandepoele 
K, Martens L, Vandesompele J, Mestdagh P. An update 
on LNCipedia: a database for annotated human lncRNA 
sequences. Nucleic acids research. 2015; 43:4363-4364.
6. Ponting CP, Oliver PL, Reik W. Evolution and functions of 
long noncoding RNAs. Cell. 2009; 136:629-641.
7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, 
Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter 
J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, 
Botstein D. Repeated observation of breast tumor subtypes 
in independent gene expression data sets. Proceedings of 
the National Academy of Sciences of the United States of 
America. 2003; 100:8418-8423.
8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen 
H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen 
T, Quist H, Matese JC, Brown PO, Botstein D, Lonning 
PE, et al. Gene expression patterns of breast carcinomas 
distinguish tumor subclasses with clinical implications. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2001; 98:10869-10874.
9. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey 
SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen 
LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, 
Lonning PE, Borresen-Dale AL, et al. Molecular portraits of 
human breast tumours. Nature. 2000; 406:747-752.
Oncotarget20595www.impactjournals.com/oncotarget
10. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular 
biology in breast cancer: intrinsic subtypes and signaling 
pathways. Cancer treatment reviews. 2012; 38:698-707.
11. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider 
J, Watson M, Davies S, Bernard PS, Parker JS, Perou 
CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and 
prognosis of patients with luminal B breast cancer. Journal 
of the National Cancer Institute. 2009; 101:736-750.
12. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, 
Spandidos DA, Stathopoulos EN. MicroRNA expression 
analysis in triple-negative (ER, PR and Her2/neu) breast 
cancer. Cell Cycle. 2011; 10:507-517.
13. Wright MW. A short guide to long non-coding RNA gene 
nomenclature. Human genomics. 2014; 8:7.
14. Fromont G, Godet J, Peyret A, Irani J, Celhay O, Rozet F, 
Cathelineau X, Cussenot O. 8q24 amplification is associated 
with Myc expression and prostate cancer progression and 
is an independent predictor of recurrence after radical 
prostatectomy. Human pathology. 2013; 44:1617-1623.
15. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, 
Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, 
Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, 
Mills GB, Huntsman DG, et al. Amplification of PVT1 
contributes to the pathophysiology of ovarian and breast 
cancer. Clinical cancer research 2007; 13:5745-5755.
16. Comprehensive molecular portraits of human breast 
tumours. Nature. 2012; 490:61-70.
17. Lee S, Kopp F, Chang TC, Sataluri A, Chen B, Sivakumar 
S, Yu H, Xie Y, Mendell JT. Noncoding RNA NORAD 
Regulates Genomic Stability by Sequestering PUMILIO 
Proteins. Cell. 2015.
18. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, 
Viale A, Olshen AB, Gerald WL, Massague J. Genes that 
mediate breast cancer metastasis to lung. Nature. 2005; 
436:518-524.
19. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, 
A’Hern R, Salter J, Detre S, Hills M, Walsh G. Prognostic 
value of Ki67 expression after short-term presurgical 
endocrine therapy for primary breast cancer. Journal of the 
National Cancer Institute. 2007; 99:167-170.
20. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, 
Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall 
GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, 
Silver PA, Gingeras TR, et al. Genome-wide analysis of 
estrogen receptor binding sites. Nature genetics. 2006; 
38:1289-1297.
21. Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, 
Inoue K. Classical and Novel Prognostic Markers for Breast 
Cancer and their Clinical Significance. Clinical Medicine 
Insights Oncology. 2010; 4:15-34.
22. Couch FJ, Nathanson KL, Offit K. Two decades after 
BRCA: setting paradigms in personalized cancer care and 
prevention. Science. 2014; 343:1466-1470.
23. Harbeck N, Sotlar K, Wuerstlein R, Doisneau-Sixou S. 
Molecular and protein markers for clinical decision making 
in breast cancer: today and tomorrow. Cancer treatment 
reviews. 2014; 40:434-444.
24. van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart 
AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, 
Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts 
C, Linsley PS, Bernards R, Friend SH. Gene expression 
profiling predicts clinical outcome of breast cancer. Nature. 
2002; 415:530-536.
25. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner 
FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, 
Wickerham DL, Bryant J, Wolmark N. A multigene assay 
to predict recurrence of tamoxifen-treated, node-negative 
breast cancer. The New England journal of medicine. 2004; 
351:2817-2826.
26. Zhao Y, Li H, Fang S, Kang Y, Wu W, Hao Y, Li Z, Bu 
D, Sun N, Zhang MQ, Chen R. NONCODE 2016: an 
informative and valuable data source of long non-coding 
RNAs. Nucleic acids research. 2015.
27. Takagi M, Absalon MJ, McLure KG, Kastan MB. 
Regulation of p53 translation and induction after DNA 
damage by ribosomal protein L26 and nucleolin. Cell. 2005; 
123:49-63.
28. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong 
DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska 
P, Kong B, Li R, West RB, van de Vijver MJ, et al. Long 
non-coding RNA HOTAIR reprograms chromatin state to 
promote cancer metastasis. Nature. 2010; 464:1071-1076.
29. Sorensen KP, Thomassen M, Tan Q, Bak M, Cold S, 
Burton M, Larsen MJ, Kruse TA. Long non-coding RNA 
HOTAIR is an independent prognostic marker of metastasis 
in estrogen receptor-positive primary breast cancer. Breast 
cancer research and treatment. 2013; 142:529-536.
30. Gokmen-Polar Y, Vladislav IT, Neelamraju Y, Janga SC, 
Badve S. Prognostic impact of HOTAIR expression is 
restricted to ER-negative breast cancers. Scientific reports. 
2015; 5:8765.
31. Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST, 
Risch HA, Mu L, Canuto EM, Gregori G, Benedetto C, 
Yu H. Association of large noncoding RNA HOTAIR 
expression and its downstream intergenic CpG island 
methylation with survival in breast cancer. Breast cancer 
research and treatment. 2012; 136:875-883.
32. Wang K, Guo WX, Li N, Gao CF, Shi J, Tang YF, Shen 
F, Wu MC, Liu SR, Cheng SQ. Serum LncRNAs Profiles 
Serve as Novel Potential Biomarkers for the Diagnosis of 
HBV-Positive Hepatocellular Carcinoma. PloS one. 2015; 
10:e0144934.
33. Xu N, Chen F, Wang F, Lu X, Wang X, Lv M, Lu C. 
Clinical significance of high expression of circulating 
serum lncRNA RP11-445H22.4 in breast cancer patients: 
a Chinese population-based study. Tumour biology. 2015; 
36:7659-7665.
Oncotarget20596www.impactjournals.com/oncotarget
34. Lu J, Xie F, Geng L, Shen W, Sui C, Yang J. Investigation 
of serum lncRNA-uc003wbd and lncRNA-AF085935 
expression profile in patients with hepatocellular carcinoma 
and HBV. Tumour biology. 2015; 36:3231-3236.
35. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin 
AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, 
Groskopf J. PCA3: a molecular urine assay for predicting 
prostate biopsy outcome. The Journal of urology. 2008; 
179:1587-1592.
36. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, 
Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami 
E, Sander C, Schultz N. Integrative analysis of complex 
cancer genomics and clinical profiles using the cBioPortal. 
Science signaling. 2013; 6:pl1.
37. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy 
BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin 
Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio 
cancer genomics portal: an open platform for exploring 
multidimensional cancer genomics data. Cancer discovery. 
2012; 2:401-404.
38. Gray R. A Class of K-Sample Tests for Comparing the 
Cumulative Incidence of a Competing Risk. The Annals of 
Statistics. 1988; 16:1141-1154.
39. Pfaffl MW. A new mathematical model for relative 
quantification in real-time RT-PCR. Nucleic acids research. 
2001; 29:e45.
40. Ho TT, Zhou N, Huang J, Koirala P, Xu M, Fung R, Wu 
F, Mo YY. Targeting non-coding RNAs with the CRISPR/
Cas9 system in human cell lines. Nucleic acids research. 
2015; 43:e17.
41. Wong N, Liu W, Wang X. WU-CRISPR: characteristics 
of functional guide RNAs for the CRISPR/Cas9 system. 
Genome biology. 2015; 16:218.
42. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang 
F. Genome engineering using the CRISPR-Cas9 system. 
Nature protocols. 2013; 8:2281-2308.
43. Wu F, Chiocca S, Beck WT, Mo YY. Gam1-associated 
alterations of drug responsiveness through activation 
of apoptosis. Molecular cancer therapeutics. 2007; 
6:1823-1830.
